01st week of 2016 patent applcation highlights part 9 |
Patent application number | Title | Published |
20160000807 | COMPOUND AND METHOD FOR THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE CONDITIONS - A reagent selected from cholestenoic acid or an inhibitor of an enzyme in the cholestenoic acid biosynthetic or metabolic pathway for use in the treatment of neurodegenerative conditions. In particular, the reagent is a cholestenoic acid of a particular form, such as 3β,7α-dihydroxycholest-5-en-26-oic (3β,7α-diHCA), not previously associated with neural tissue or CSF. Pharmaceutical compositions, methods of treatment or prevention of neurodegenerative conditions as well as diagnostic methods and novel biomarkers form further aspects of the invention. | 2016-01-07 |
20160000808 | ANDROGEN RECEPTOR DOWN-REGULATING AGENTS AND USES THEREOF - The present disclosure provides the design and synthesis of novel steroidal compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant. The compounds are potential agents for the treatment of all forms of prostate cancer and other diseases that depend on functional AR. | 2016-01-07 |
20160000809 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF EYE PAIN, CONTAINING PGE2 SYNTHESIS INHIBITOR - The present invention relates to a pharmaceutical composition for the treatment of eye pain, containing a PGE2 synthesis inhibitor. The use of the pharmaceutical composition for the prevention or treatment of eye pain according to the present invention, which contains the PGE2 synthesis inhibitor as an active ingredient, makes it possible to alleviate the symptoms of eye pain by selectively inhibiting the PGE2 expression level, and also has the advantages of treating and preventing xerophthalmia and of overcoming and preventing eye discomfort caused by various inflammation-inducing circumstances including following surgery. Also, by using a kit for detecting the amount of PGE2, PGD2 and COX2, the present invention makes it possible to easily diagnose eye-pain symptoms in clinical practice, and can be widely used in checking the state not only of patients having xerophthalmia but also patients following eye surgery. | 2016-01-07 |
20160000810 | Method For Treating Eye Diseases - The present invention provides a pharmaceutical composition for removing drusen, suppressing formation of drusen, and/or treating and/or preventing age-related macular degeneration comprising the compound of formula (I) wherein Ra is independently selected from the group consisting of halo, hydroxy, alkyl, halo-substituted alkyl, aryl, halo- or alkyl-substituted aryl, alkoxy, hydroxy- or carboxy-substituted alkoxy, aryloxy, halo- or alkyl-substituted aryloxy, CHO, C(O)-alkyl, C(O)-aryl, C(O)-alkyl-carboxyl, C(O)-alkylene-carboxy ester and cyano, and m is an integer selected from 0 to 4. | 2016-01-07 |
20160000811 | TREATMENT OF GRAFT VERSUS HOST DISEASE IN TRANSPLANT PATIENTS - The present invention relates to a method of treating patients who undergo hematopoietic stem cell transplantation (HSCT) with peripheral blood mobilized stem cells for hematological malignancies and for whom the risk for severe acute graft versus host disease (GVHD) is considerable. | 2016-01-07 |
20160000812 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS - Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject. | 2016-01-07 |
20160000813 | BORON-CONTAINING SMALL MOLECULES - This invention provides novel compounds, methods of using the compounds, and pharmaceutical formulations comprising the compounds. | 2016-01-07 |
20160000814 | TREATMENT OF CYSTIC DISEASES - The invention described herein pertains to the treatment of cystic diseases. More particularly, the invention described herein relates to methods for treating cystic disease using one or more lysophosphatidic acid antagonists, TMEM16a inhibitors, and/or peroxisome proliferator-activated receptor modulators. | 2016-01-07 |
20160000815 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS - Methods of treating psychiatric disorders are provided which include administration of one or more anti-epileptic agents and, optionally, one or more a psychostimulants. Also provided are pharmaceutical compositions comprising, in combination, one or more anti-epileptic agents and one or more psychostimulants. Psychiatric disorders include those associated with impaired cognitive processing, degenerative disorders such as Mild Cognitive Impairment, Parkinson's disease, dementia, non-compliance with therapeutic regimes and eating disorders, although without limitation thereto. | 2016-01-07 |
20160000816 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes. | 2016-01-07 |
20160000817 | TREATMENT OF OCULAR DISORDERS - The invention includes a method of treating an intraocular disorder in a mammal, the method comprising administering to the mammal a Very Late Antigen-4 (VLA-4) antagonist for the treatment of selected ocular disorders. | 2016-01-07 |
20160000818 | COMPOSITIONS INCLUDING TRICIRIBINE AND ONE OR MORE PLATINUM COMPOUNDS AND METHODS OF USE THEREOF - This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2016-01-07 |
20160000819 | Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer. | 2016-01-07 |
20160000820 | COMPOSITIONS AND METHODS FOR TREATING CARBON MONOXIDE AND/OR CYANIDE POISONING - Compositions, methods and kits for treating victims of carbon monoxide and/or cyanide poisoning and/or nitric acid-induced vasoplagia are provided. The compositions comprise reduced forms of Vitamin B12 such as reduced hydroxocobalamin or reduced cobinamide, and typically comprise at least one reducing agent (e.g. ascorbic acid). The compositions are generally produced, stored and delivered under reducing, usually anaerobic, conditions in order to preserve the desired oxidation state when introduced into the blood stream of a recipient. | 2016-01-07 |
20160000821 | MICRO-RNAS AND COMPOSITIONS COMPRISING SAME FOR THE TREATMENT AND DIAGNOSIS OF SEROTONIN-, ADRENALIN-, NORADRENALIN-, GLUTAMATE-, AND CORTICOTROPIN-RELEASING HORMONE- ASSOCIATED MEDICAL CONDITIONS - microRNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone-associated medical conditions are provided. | 2016-01-07 |
20160000822 | POLOXAMER THERAPY FOR HEART FAILURE - Provided methods of administering poloxamer 188 for treating heart failure by only a single short relatively high dose infusion, or by regimen that includes the single infusion followed by additional infusions at intervals of 1-4 weeks. | 2016-01-07 |
20160000823 | METHODS AND COMPOSITIONS FOR IMPROVING HEMOSTASIS - Provided are methods and uses of polyoxyethylene/polyoxypropylene copolymers (poloxamers) for treating bleeding and hemorrhage in animals, including human or veterinary subjects, and thus, treating hemostatic dysfunction, resulting from, for example, drug, disease-, trauma- or surgical-induced bleeding. Polyoxyethylene/polyoxypropylene copolymers improve hemostasis and aid in the control of bleeding. Methods for treating strokes using the polyoxyethylene/polyoxypropylene copolymers also are provided. Devices, products and compositions for treating or preventing hemostatic dysfunction are provided. | 2016-01-07 |
20160000824 | TOXICITY ENHANCING COMPOUNDS AND METHODS - A method of treating a tumor or cancer in a subject includes administering to cancer or tumor cells of the subject a radiation sensitizing amount of a poly(ethylene oxide)-poly(propylene oxide) copolymer and administering radiation therapy to the cancer or tumor cells sensitized by the poly(ethylene oxide)-poly(propylene oxide) copolymer. | 2016-01-07 |
20160000825 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 2016-01-07 |
20160000826 | Gargle Method to Reduce the Duration of Common Cold Symptoms - A method of reducing the presence, duration, severity, or symptoms of the common cold entails the administration of a nonalcoholic antiviral remedy to a subject in need of such treatment, preferably in the form of a gargle. | 2016-01-07 |
20160000827 | ORALLY ADMINISTERED ADSORBENT, THERAPEUTIC AGENT FOR RENAL DISEASE, AND THERAPEUTIC AGENT FOR LIVER DISEASE - An object of the present invention is to provide an orally administered adsorbent capable of adsorbing large quantities of tryptophan or indoxyl sulfate in the presence of bile acid. Accordingly, the above object can be solved by an orally administered adsorbent characterized by containing surface-modified spherical activated carbon having bulk density from 0.30 g/mL to 0.46 g/mL, a specific surface area determined by the Brunauer-Emmett-Teller (BET) method of not less than 1900 m | 2016-01-07 |
20160000828 | A CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASE - The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for the use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases. | 2016-01-07 |
20160000829 | METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes. | 2016-01-07 |
20160000830 | USE OF ALLOGENEIC INTERSTITIAL VESSEL-LAYER CELL AND ALLOGENEIC MESENCHYMAL PROGENITOR CELL FOR PREVENTING OR TREATING OSTEOARTHRITIS - Provided are uses of allogeneic interstitial vessel-layer cells and allogeneic mesenchymal progenitor cells in the preparation of a pharmaceutical composition for preventing or treating osteoarthritis (OA). Also provided is a pharmaceutical composition containing the allogeneic interstitial vessel-layer cells and the allogeneic mesenchymal progenitor cells. | 2016-01-07 |
20160000831 | COMPOSITION FOR TREATING INFLAMMATORY BRAIN DISEASES WHICH INCLUDES STEM CELL AS ACTIVE INGREDIENT - The present invention relates to a composition for treating inflammatory brain diseases which includes a stem cell as an active ingredient. When the stem cell according to the present invention is directly administered to animal models with inflammatory brain diseases, a brain damage caused by inflammation such as edema is significantly reduced, the weight-loss phenomenon is greatly improved, and the like, and thus the cell has an excellent effect in treating inflammatory brain diseases and consequently can be used effectively in treating inflammatory brain diseases. | 2016-01-07 |
20160000832 | STEM CELLS DERIVED FROM BONE MARROW FOR TISSUE REGENERATION - The invention relates to stems cells derived from bone marrow, and uses thereof in tissue regeneration. | 2016-01-07 |
20160000833 | METHOD OF PREPARING DEER BONE EXTRACT HAVING INCREASED AMOUNT OF GANGLIOSIDE - Disclosed herein is a method of preparing a deer bone extract in which deer bones are subjected to extraction at normal pressure and extraction under pressure to minimize decomposition of deer bone-derived gangliosides by heat and to increase protein extraction yield. | 2016-01-07 |
20160000834 | METHODS AND COMPOSITIONS FOR TISSUE THERAPY AND ANALYSIS - Methods and compositions comprising a biomaterial that are useful for treating a subject with a condition are described. More specifically, methods of treating a subject with a cardiovascular condition comprising delivering a biomaterial comprising extracellular matrix, and delivering a therapeutic cardiac device or therapeutic agents to the subject are described. In addition, methods of delivering extracellular matrix to a subject are also described. | 2016-01-07 |
20160000835 | HUMAN UTERINE CERVICAL STEM CELL POPULATION AND USES THEREOF - The present invention relates to a method for isolating stem cells comprising preparing a cell suspension from uterine cervix tissue, to the stem cells isolated by said method, and to the conditioned medium obtained from the culture of said stem cells. The invention also encompasses the use of said stem cells or conditioned medium for treating or preventing cancer, precancerous lesions, inflammatory diseases, autoimmune diseases, chronic pathologies or infectious diseases, diseases associated to tissue loss, or for use in diagnostic, prognostic or treatment of fertility disorders, as well as for cosmetic treatment. | 2016-01-07 |
20160000836 | PREPARING TOOTH-LIKE STRUCTURE USING STEM CELL - The usage of a stem cell in preparation of a tooth-like structure is provided. And a culture medium, a method for preparing an epithelial-like cell, a kit for preparing an ameloblast, a method for preparing an ameloblast are also provided. Specifically, the culture medium comprises a basal medium, which is DMEM/F 12 medium; N2 supplement; retinoic acid; and BMP-4. | 2016-01-07 |
20160000837 | COMPOSITIONS AND METHODS TO ALTER GUT MICROBIAL FERMENTATION USING SULFATE-REDUCING BACTERIA - The present invention provides combinations and methods for changing the representation of at least one sulfate-reducing bacterial species in a subject's gut, thereby changing microbial fermentative activity in the gut in the subject. | 2016-01-07 |
20160000838 | Use of Faecalibacterium Prausnitzii Htf-f (DSM 26943) to Suppress Inflammation - The present invention relates to medicine, particularly immunology and gastroenterology. Specifically, it relates to probiotic bacteria and extracts thereof for therapeutic use for the treatment of inflammatory disorders such as inflammatory bowel disease. Provided is a composition comprising as active ingredient | 2016-01-07 |
20160000839 | COMPOSITIONS AND METHOD FOR TREATMENT AND PROPHYLAXIS OF INFLAMMATORY BOWEL DISEASE - Methods and compositions for treating inflammatory bowel disease involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic. The practice of the invention may reduce or eliminate the use of immunosuppressants in the treatment and management of IBD. | 2016-01-07 |
20160000840 | Probiotic Strains for Treating and/or Preventing Diarrhea - The present invention relates to a method of selecting or identifying probiotic strains capable of acting on the absorption of water in the colon, and use thereof as medicinal products in the treatment and/or prevention of diarrhea. The invention relates in particular to the strain of | 2016-01-07 |
20160000841 | Compositions and Methods for Promoting Growth of Beneficial Microbes to Treat or Prevent Disease or Prolong Life - Inoculation of ATM-deficient mice with probiotic microorganisms, such as | 2016-01-07 |
20160000842 | ONCOLYTIC VIRUS - Embodiments of the present disclosure concern oncolytic viruses, such as vaccinia virus, for example, for the treatment of cancer, wherein the viruses encode an engager molecule having an activation domain that recognizes a cell molecule, such as CD3, for example, on T cells and an antigen recognition domain that recognizes a tumor antigen, such as EphA2, HER2, GD2, or Glypican-3, for example. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example. Methods of treating cancer using one or more of the compositions are encompassed in the disclosure. | 2016-01-07 |
20160000843 | HIGH CANNABIDIOL CANNABIS STRAINS - The invention described herein relates to a cannabis cultivar that produces high concentrations of cannabidiol. The invention further relates to preparations and products derived from the cannabis cultivar. Also provided are methods of treating conditions that are treatable by cannabidiol. by administering a preparation or product derived from the cannabis cultivar. | 2016-01-07 |
20160000844 | A COMPOSITION FOR IMPROVING JOINT HEALTH, OR FOR PREVENTING AND TREATING RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS - The present invention relates to a composition for helping with joint health or preventing, alleviating or treating rheumatoid arthritis and osteoarthritis, which is based on the results of tests conducted using an inflammatory cell model, an osteoarthritis animal model and an acute arthritis animal model. | 2016-01-07 |
20160000845 | EXTRACT OF TRIGONELLA FOENUM-GRAECUM - Disclosed herein is an extract obtainable from | 2016-01-07 |
20160000846 | HERBAL COMPOSITION AND A METHOD OF TREATING UTERINE FIBROIDS - The invention discloses an herbal composition of treating uterine fibroid. The herbal composition comprises | 2016-01-07 |
20160000847 | METHOD OF USING CISTANCHE TUBULOSA EXTRACT FOR PREPARING DRUGS OR FOOD TO PROTECT EYE CELLS - This invention provides a method of using of extract of | 2016-01-07 |
20160000848 | Bioactive Compositions From Fruit and Methods for Their Production - The present invention relates to bioactive fractions (ingredients) derived from fruit juices. The bioactive fractions are either free of or substantially free of patulin and protein. Further, the bioactive fractions have antioxidant, free radical scavenging, moisturizing and buffering properties. The present invention also relates to a method for isolating bioactive fractions that are derived from fruit juices and are free or substantially free of protein and patulin. The present invention also relates to a method for preparing a bioactive fractions derived from fruit juices that are stabilized and are either free of or substantially free of patulin and protein. | 2016-01-07 |
20160000849 | COMPOSITION FOR REMEDYING OR TREATING RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS - The present invention relates to the composition according to the present invention, which has not only the effect of suppressing inflammation and pain, which are the common symptoms of acute and chronic arthritis, but also the effect of alleviating movement disorders, which are the symptoms of chronic arthritis. | 2016-01-07 |
20160000850 | MEDICINAL COMPOSITION FOR LIVER DISEASES - The invention provides a composition containing extracts from | 2016-01-07 |
20160000851 | Bioactive Botanical Compositions and Uses Thereof - The present invention relates to a composition having enhanced anti-inflammatory properties and to a method for inhibiting inflammation in biological tissue, including but not limited to skin Skin inflammation includes any undesirable effect produced in or on the surface of skin, including but not limited to irritation, redness, swelling, local temperature elevation, fissures, desquamation, itch, pain, sensitivity, abrasion, discoloration, and bleeding or the like, and combinations thereof. The invention demonstrates that certain plant fractions, such as the serum fractions of | 2016-01-07 |
20160000852 | NUTRIENT COMBINATIONS FOR AFFECTING AN AGING PROCESS - A composition comprising an effective amount of a combination of mitochondrial nutrients sufficient to affect mitochondrial function. A method of affecting an aging process in a subject comprising administering to a subject an effective amount of a combination of mitochondrial nutrients sufficient to affect an aging process. A method of identifying a combination of mitochondrial nutrients sufficient to affect an aging process in a subject, the method comprising: administering a combination of mitochondrial nutrients to a subject; and determining whether the mitochondrial nutrients affect an aging process in the subject. | 2016-01-07 |
20160000853 | NUTRICEUTICAL GELS - A nutriceutical food product includes a solid matrix and a liquid combined into a gel. The nutriceutical food product may include an immune modulator, such as transfer factor and/or a nanofraction immune modulator. A fruit component may be included in the nutriceutical food product. The fruit component may include at least one oligoproanthocyanidin-containing fruit, such as açai. | 2016-01-07 |
20160000854 | TREATMENT OF DNA DAMAGE AND MITOCHONDRIAL DYSFUNCTION USING PALM FRUIT JUICE - Methods, compositions and kits for the prevention and treatment of mitochondrial dysfunction, mitochondrial DNA damage and genomic DNA damage are provided. The methods use the administration of palm fruit juice and/or compositions containing phenolic compounds present in palm fruit juice. The methods, compositions, and kits can be used to reduce DNA damage in subjects being treated with nucleoside reverse transcriptase inhibitors, such as patients having HIV or AIDS. | 2016-01-07 |
20160000855 | OXIDIZED PROTEIN HYDROLASE ACTIVITY ENHANCING AGENT - The present invention provides a novel oxidized protein hydrolase activity enhancing agent. The oxidized protein hydrolase activity enhancing agent of the present invention contains at least one kind of plant extract obtained from a plant selected from the group consisting of water chestnut, stevia, rosemary, thyme, chrysanthemum, savory, mugwort, chestnut, spearmint, marjoram, peppermint, lemon balm, allspice, perilla, basil, and caraway. | 2016-01-07 |
20160000856 | COMPOSITION FOR PREVENTING CANCER AND TREATING CANCER AND INTENSIFYING THE EFFECTS OF OTHER ANTICANCER DRUGS - This invention relates to a composition derived from Chinese herbal medicines, medicinal plants and extracts thereof, and to its use for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs. More specifically, the composition of the present invention is derived from various Chinese herbal medicines or medicinal plants which have a long history of human consumption. The composition of the invention is obtained through specific techniques and has revealed good cytotoxicities on Malignant Melanoma Cells, Prostate Cancer Cells and Colon Cancer Cells, Lung Cancer Cells, Stomach Cancer Cells, Breast Cancer Cells and Liver Cancer Cells. The composition of the invention has also revealed obvious intensifying the effects of other anticancer drugs. Cancer presents special problems to the medical community which the present invention address, | 2016-01-07 |
20160000857 | Method of Regulating Glucose Metabolism, and Reagents Related Thereto - The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinenmia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis. | 2016-01-07 |
20160000858 | COMPOSITIONS AND METHODS FOR MITIGATING SKIN IRRITATION AND ENHANCING SKIN BARRIER FUNCTION - Methods and compositions for cell regeneration and decreased irritation of mammalian skin cells are provided, wherein the compositions include a synergistic combination of two or more oligopeptides. The compositions may advantageously be applied to mammalian skin to effect a regeneration of skin cells and to effect a reduction in inflammation and redness experienced by the skin. Skin cleansing and sanitizing compositions are provided that include at least one oligopeptide, wherein the compositions have reduced irritancy potential. | 2016-01-07 |
20160000859 | PEPTIDE ADDITIVES FOR ENHANCING ACCEPTANCE AND INGESTION OF EDIBLES BY RODENTS AND USES THEREOF - Methods of using of guanylin family peptides to induce food or odor preferences in mammals are provided, along with methods for inducing feeding responses in mammals, and methods of controlling pest populations of mammals, such as rodents. | 2016-01-07 |
20160000860 | ENHANCEMENT OF BMP RETENTION - The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical comorbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders. | 2016-01-07 |
20160000861 | Compositions and Treatments of Metabolic Disorders Using FGF Binding Protein 3 - The invention relates to methods of treating a metabolic disorder in a subject, the method comprising administering fibroblast growth factor binding protein 3 (FGFBP3) or a variant thereof to a subject in need of treatment of a metabolic disorder. | 2016-01-07 |
20160000862 | USE OF PEDF-DERIVED POLYPEPTIDES FOR PROMOTING MUSCLE OR TENDON REGENERATION OR ARTERIOGENESIS - A method for promoting muscle or tendon regeneration, and/or arteriogenesis in a subject includes administering to the subject a pharmaceutical composition that contains a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues and has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. The synthetic peptide may have the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 9. | 2016-01-07 |
20160000863 | HEMOSTATIC COMPOSITIONS - The invention provides a composition comprising a combination of lipidated tissue factor and thrombin, wherein the amount of thrombin is comprised from 1 to 30 IU per gram of composition, and the amount of lipidated tissue factor is comprised from 5 to 150 ng per gram of composition. The present invention also provides pharmaceutical or veterinary compositions as well as hemostatic compositions. The compositions of the invention are useful in the treatment of hemorrhages. | 2016-01-07 |
20160000864 | PHARMACEUTICAL COMPOSITION COMPRISING RECOMBINANT HEMOGLOBIN PROTEIN OR SUBUNIT-BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT - The present invention provides a pharmaceutical composition containing recombinant hemoglobin protein or tetramer or dimer or subunit for tissue oxygenation and treating cancer. The recombinant hemoglobin protein or tetramer or dimer or subunit-based therapeutic agent is also effective for treating cancer. The recombinant hemoglobin or tetramer or dimer or its subunit moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The recombinant hemoglobin or tetramer or dimer or its subunit-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent, radiotherapeutic agent, anti-cancer protein drug to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. | 2016-01-07 |
20160000865 | COMPOSITIONS AND METHODS RELATING TO INDUCTION OF INTESTINAL STEM CELL HOMEOGENESIS AND/OR REGENERATION - The present invention relates to compositions and methods for inducing intestinal stem cell homeogenesis and/or regeneration within intestinal tissue expressing Robo1 through administration of a Rspo1 agent and a Slit2 agent. Administration of such agents results in, for example, binding of the Rspo1 agent and Slit2 agent with Robo1, resulting in, for example, binding of the CC3 motif of Robo1 with LRP6, resulting in phosphorylation of LRP6, and ultimately, induction of intestinal stem cell homeogenesis and/or regeneration. In certain embodiments, such administration of a Rspo1 agent and a Slit2 agent is used to protect and/or prevent intestinal tissue damage resulting from exposure to an intestinal tissue damaging event (e.g., radiation). The agents and related compositions additionally find use in diagnostic and research settings. | 2016-01-07 |
20160000866 | CTHRC1 RECEPTOR AND METHODS OF USE THEREOF - The invention features compositions and methods for treating and preventing steatosis, osteoporosis, and muscle weakness featuring the receptor for the collagen triple helix repeat containing-1 (Cthrc1) protein. | 2016-01-07 |
20160000867 | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNE SYSTEM - A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a T | 2016-01-07 |
20160000868 | RECEPTOR-TARGETING REAGENTS - The present disclosure features, inter alia, receptor-targeting reagents (e.g., immunotoxic receptor-targeting reagents), which are useful in, e.g., methods of binding a receptor-targeting reagent to a cell and methods for treating a variety of disorders such as, but not limited to, cancers and inflammatory disorders. Also featured are methods, compositions, and kits useful for selecting an appropriate treatment modality for a subject (e.g., a subject with a cancer or inflammatory disorder) and/or treating a variety of disorders such as cell proliferative disorders. | 2016-01-07 |
20160000869 | METHODS OF TREATING IPEX SYNDROME USING TOXIN-BASED PHARMACEUTICAL COMPOSITIONS - Disclosed herein are methods of treating immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) comprising administering a toxin-based therapeutic peptide, such as an ShK-based peptide. The peptide can include an acid or amide at the C-terminus and/or the peptide can be attached to an organic or inorganic chemical entity that has an anionic charge. | 2016-01-07 |
20160000870 | METHODS AND COMPOSITIONS FOR DELIVERING INTERLEUKIN-1 RECEPTOR ANTAGONIST - Methods, systems, and compositions related to generating and using a solution rich in interleukin-1 receptor antagonist are provided. Methods include contacting a liquid comprising white blood cells with a solid extraction material and stimulating with an electromagnetic field to activate production of interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist can be separated from the solid extraction material. Methods for treating a site of inflammation in a patient include administering the solution rich in interleukin-1 receptor antagonist to the site of inflammation. | 2016-01-07 |
20160000871 | TIE2 RECEPTOR ACTIVATION FOR GLAUCOMA - This invention relates to the production and genotyping of mice lacking both Angiopoietin 1 and Angiopoietin 2. This invention also relates to the use of Tie2 receptor activation for treatment of open angle glaucoma, congenital glaucoma and cystic kidney disease, and more specifically to the use of angiopoietin 1 recombinant proteins, peptides, VE-PTP phosphatase inhibitors, and Tie2− peptomimetics to improve lymphatic drainage in the Schlemm's canal and corneal limbal lymphatic system for open angle glaucoma and congenital glaucoma patients, and to slow and/or reduce the growth of cysts in patients with cystic kidney disease. | 2016-01-07 |
20160000872 | EXERCISE-REGULATED ADIPOKINES AS THERAPY FOR DIABETES MANAGEMENT - The present invention is related to methods and compositions effective in regulating glycemic control in subject individuals in need of the regulation of glycemic control. Said individuals may have diabetes or be prediabetic condition receive therapeutically effective amounts of identified secreted proteins in an amount suitable for modulating glycemic control and to thereby treat or prevent diabetes in said subject. | 2016-01-07 |
20160000873 | AGENTS WHICH INDUCE LYMPHANGIOGENESIS FOR USE IN THE TREATMENT OF CYSTIC KIDNEY DISEASE - The invention relates to methods and materials for treating a renal cystic disease in a subject suffering therefrom, the methods comprising administering the compound to the subject, wherein the compound is a lymphangiogenic agent such as an agonist of VEGFR-3, or a nucleic acid encoding said agent. | 2016-01-07 |
20160000874 | Modulating Ischemic Injury - The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents. | 2016-01-07 |
20160000875 | GM-CSF FOR TREATMENT OF CHRONIC ORAL MUCOSITIS - The present invention relates to compositions comprising granulocyte-macrophage colony-stimulating factor (GM-CSF), or homologues thereof, and its use for treatment, prevention or alleviation of oral mucositis. The composition is preferably an aqueous solution forlocaloral administration. | 2016-01-07 |
20160000876 | IL-33 and Treatment of Neurodegenerative Diseases - The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to therapies of neurodegenerative diseases. More specifically, the present invention relates to interleukin-33 (IL-33), a fragment thereof, a polynucleotide encoding IL-33 or a fragment thereof for use in treatment or prevention of a neurodegenerative disease involving inflammation in a subject and to a method of treating or preventing a neurodegenerative disease involving neuroinflammation in a subject. Still, the present invention relates to IL-33, a fragment thereof, a polynucleotide encoding IL-33 or a fragment thereof for use in improving or restoring neuronal function or endogenous neuronal repair mechanisms, or enhancing endogenous neurogenesis, oligodendrogenesis or neuronal differentiation in a subject. Also, the present invention relates to a method of improving or restoring neuronal function or endogenous neuronal repair mechanisms, or enhancing endogenous neurogenesis, oligodendrogenesis or neuronal differentiation in a subject. | 2016-01-07 |
20160000877 | COMPOSITIONS AND METHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITY - The γc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. The present embodiments relate to the design of peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. In several embodiments, peptide antagonists exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members. | 2016-01-07 |
20160000878 | Treatment of Prior Disease With Oral Interferon Alpha - The present disclosure is directed to compositions and methods for treating prion diseases through oral administration of low doses of interferon-alpha. In one embodiment a composition is administered comprising interferon-alpha and trehalose. | 2016-01-07 |
20160000879 | Treatment of Smell and Taste Disorders Using Orally Administered Interferon-Alpha - The present disclosure is directed to the use of interferon to treat smell and taste disorders. In one embodiment a composition comprising interferon-alpha is administered orally to treat a patient suffering from diminished or distorted senses of smell and taste due to aging, medication usage, viral illness, physical trauma or a chronic medical condition. | 2016-01-07 |
20160000880 | Methods for Treating Multiple Sclerosis - The present invention provides methods for treating or limiting development of multiple sclerosis by administering angiotensin peptides to a subject with multiple sclerosis or at risk of developing multiple sclerosis. | 2016-01-07 |
20160000881 | Oral Drug Devices and Drug Formulations - Compositions containing a drug to be delivered and at least one chemical permeation enhancer (CPE), and methods of making and using these compositions are described herein. In a preferred embodiment, the compositions contain two or more CPEs which behave in synergy to increase the permeability of the epithelium, while providing an acceptably low level of cytotoxicity to the cells. The concentration of the one or more CPEs is selected to provide the greatest amount of overall potential (OP). Additionally, the CPEs are selected based on the treatment. CPEs that behave primarily by transcellular transport are preferred for delivering drugs into epithelial cells. CPEs that behave primarily by paracellular transport are preferred for delivering drugs through epithelial cells. Also provided herein are mucoadhesive oral dosage forms. In a preferred embodiment, the oral dosage form is a multi-compartmental device, containing (i) a supporting compartment, (ii) drug compartment and (iii) mucoadhesive compartment. | 2016-01-07 |
20160000882 | PEPTIDES FOR USE IN THE TOPICAL TREATMENT OF RETINAL NEURODEGENERATIVE DISESASES, IN PARTICULAR IN EARLY STAGES OF DIABETIC RETINOPATHY AND OTHER RETINAL DISEASES IN WHICH NEURODEGENERATION PLAYS AN ESSENTIAL ROLE - The invention relates to peptides with a sequence length from 13 to 50 amino acids, the N-terminal region of said peptides consisting in the sequence HXaa | 2016-01-07 |
20160000883 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES - The invention relates to methods for treating metabolic disorders, including diabetes by using a combination of an acylated glucagon analogue and an insulin analogue. The invention also features a kit that includes an acylated glucagon analogue and an insuline analogue. | 2016-01-07 |
20160000884 | Liquid Factor VIII Formulations - The invention is directed to a liquid, aqueous formulation of coagulation Factor VIII, comprising a Factor VIII molecule, a calcium salt in a concentration of more than 10 mM, and a saccharide and/or polyol in a concentration of at least 100 mM, wherein the formulation has a pH from 5.5-7.5. The invention furthermore provides a method for optimising a liquid formulation of coagulation Factor VIII, the method comprising the steps of: (i) Providing one or more liquid formulations comprising Factor VIII to be tested; (ii) Adding a protein denaturant to said liquid formulations, and incubating the resulting solutions for a predetermined period of time; (iii) Analysing the incubated solutions of (ii) for the presence of dissociated Factor VIII; and (iv) Selecting one or more formulation(s) having a desired low level of dissociated Factor VIII. | 2016-01-07 |
20160000885 | Methods for Stabilizing Corneal Tissue - Methods of stabilizing collagen fibrils in a cornea are disclosed. The stabilization may be effected by treating the cornea with a protein that crosslinks collagen fibrils, such as decorin. The stablization methods include treatment of corneas before, during, or after a surgical procedure, treatment of keratectasia, and treatment of keratoconus. | 2016-01-07 |
20160000886 | NANOSTRUCTURED ACTIVE THERAPEUTIC VEHICLES AND USES THEREOF - The present invention provides nano structured active therapeutic vehicles which include a biodegradable polymeric fiber and/or thread comprising a porous particle which encapsulates an active agent. The vehicles of the present invention may be used to provide sustained release of the active agent to a subject. | 2016-01-07 |
20160000887 | COMPOSITIONS AND METHODS FOR TREATING MPSI - A vector having an expression cassette having a hIDUA gene having a sequence of SEQ ID NO: 1 or a sequence at least about 95% identical thereto which encodes a functional human alpha-L-iduronidase is provided. The vector may be production vector or a rAAV8. Also provided are compositions containing these vectors and methods of treating MPSI and the symptoms associated with Hurler, Hurle-Scheie and Scheie syndromes. | 2016-01-07 |
20160000888 | FACTOR IX POLYPEPTIDE FORMULATIONS - The present invention provides formulations comprising a Factor IX-FcRn Binding Partner (FIXFBP) polypeptide, and methods of administering FIXFBP. | 2016-01-07 |
20160000889 | COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES - A drug product comprising a combination of highly purified collagenase I and collagenase II from | 2016-01-07 |
20160000890 | THERMOSENSITIVE HYDROGEL COLLAGENASE FORMULATIONS - It is an object of the present disclosure to provide a formulation for injectable and topical collagenase, which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated. It is a further object of the disclosure to provide a slow release formulation for collagenase, which is compatible with the active ingredient and does not adversely affect its activity. Still a further object of the disclosure is to provide an injectable formulation for collagenase which can be effectively administered to a patient with a small size needle without exhibiting pre-gelation, which would interfere with the ability to deliver the required dose for treatment. Still a further object of the disclosure is to provide a water-based topical formulation for collagenase which will be more compatible with other topically used medications to achieve better results. | 2016-01-07 |
20160000891 | IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID beta (Abeta) AMINO ACID SEQUENCES AND USES THEREOF - The invention relates to immunogenic products based on mutein amyloid β (Aβ) amino acid sequences, in particular to oligomers of Aβ muteins, and to the use of said products in diagnosis, treatment and prevention of conditions such as amyloidoses, and for identifying agents capable of binding to said products. | 2016-01-07 |
20160000892 | REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF - The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention. | 2016-01-07 |
20160000893 | TARGET PEPTIDES FOR OVARIAN CANCER THERAPY AND DIAGNOSTICS - A set of target peptides are presented by HLA A*0201 on the surface of ovarian cancer cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., ovarian cancer, (b) function as immunotherapeutics in adoptive T-cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex. | 2016-01-07 |
20160000894 | IN VIVO EFFICACY OF NY-ESO-1 PLUS ADJUVANT - The invention relates to the discovery that administration of NY-ESO-1 protein, in combination with a saponin based adjuvant leads to an unexpectedly strong immune response against NY-ESO-1 expressing cells. Preferably, the combination is administered intramuscularly. | 2016-01-07 |
20160000895 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO EIMERIA OR LIMITING EIMERIA INFECTION - Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or morality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector. | 2016-01-07 |
20160000896 | Hyperbaric Device and Methods for Producing Inactivated Vaccines and for Refolding/Solubilizing Recombinant Proteins - The invention relates to hyperbaric devices for inactivating microorganisms and viruses while retaining their immunogenicity and for making and producing the soluble, disaggregated, refolded or active immunogenic or therapeutic proteins from inclusion bodies produced from prokaryotes or eukaryotes. The invention encompasses hyperbaric methods for inactivating pathogenic organisms, and methods for producing vaccine compositions using the inactivated pathogens. The hyperbarically inactivated microorganisms are safer and more immunogenic than chemically inactivated microorganisms. Similarly, the solubilized proteins have superior properties compared to more heavily aggregated proteins, including reduced non-specific immune reactions. | 2016-01-07 |
20160000897 | RECOMBINANT ANTIGENS OF PORCINE CIRCOVIRUS 2 (PCV-2) FOR VACCINE FORMULATIONS, DIAGNOSTIC KIT AND USE THEREOF - The present invention relates to the preparation of the recombinant antigen of the viral capsid of | 2016-01-07 |
20160000898 | MICRONEEDLE COATING COMPOSITION AND MICRONEEDLE DEVICE - Disclosed is a microneedle coating composition comprising a Japanese encephalitis vaccine antigen, a basic amino acid, and an acid, wherein the mole number of the acid for one mole of the basic amino acid is larger than 1/(N+1) and less than 2, where N represents the valence of the acid. | 2016-01-07 |
20160000899 | PARENTERAL NOROVIRUS VACCINE FORMULATIONS - The present invention relates to single dose parenteral vaccine compositions comprising mixtures of monovalent Norovirus virus-like particles. Methods of conferring protective immunity against Norovirus infections in a human subject by administering such compositions are also disclosed. | 2016-01-07 |
20160000900 | OLIGOMERIC INFLUENZA IMMUNOGENIC COMPOSITIONS - Embodiments are provided for network resource allocation considering user experience, satisfaction, and operator interest. An embodiment method by a network component for allocating network resources includes evaluating, for a user, a QoE for each flow of a plurality of flows in network traffic in according with a QoE model, and further evaluating, for an operator, a revenue associated with the flows in accordance with a revenue model. A plurality of priorities that correspond to the flows are calculated in accordance with the QoE for the user and the revenue for the operator. The method further includes identifying a flow of the flows with a highest value of the priorities, and allocating a network resource for the flow. In an embodiment, the QoE model is a satisfaction model that provides a measure of user satisfaction for each flow in accordance with a subscription or behavior class of the user. | 2016-01-07 |
20160000901 | Compositions and Methods for the Production of Virus-Like Particles - Compositions and methods for synthesizing virus-like particles (VLPs) and methods of use thereof are provided. | 2016-01-07 |
20160000902 | COMBINATION VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS AND INFLUENZA - The present disclosure is directed to compositions and methods for raising immune responses against influenza and respiratory syncytial virus by administering combination immunogenic composition against both viruses at the same time. The combination compositions contain an RSV component and one, two, three, four, or more influenza components. The combination compositions provide a greater immune response than that obtained by separately administering the RSV and influenza components. | 2016-01-07 |
20160000903 | NEUROATTENUATED HERPES SIMPLEX VIRUS - A mutant HSV-1 (referred to herein as KOS-NA) was generated. KOS-NA contains novel mutations in the UL39 gene, which encodes for a protein that is a large subunit of ribonucleotide reductase (i.e., ICP6). These UL39 mutations were found to alter two amino acids in ICP6 (R950H and L393P) and are responsible for attenuation of KOS-NA in vivo, and resulted in diminished ICP6 protein levels. These novel UL39 mutations regulate the expression and/or stability of ICP6 and severely impact HSV-1 pathogenesis. Mutant HSV viruses containing these mutations appear to protect against HSV infection and can serve as therapeutic vaccines to help combat preexisting HSV infection in infected individuals. | 2016-01-07 |
20160000904 | IMPROVED POXVIRAL VACCINES - The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed. | 2016-01-07 |
20160000905 | Nanoparticle Delivery of TLR Agonists and Antigens - Compositions of one or more TLR agonists and one or more antigens adsorbed or attached to the same particles or to different particles are provided. Also provided are methods for producing and using these compositions. | 2016-01-07 |
20160000906 | SYNTHETIC CONJUGATE OF CpG DNA AND T-HELP/CTL PEPTIDE - Highly effective vaccine compositions are constructed according to the methods of this invention. The methods are amenable to use with any peptidic antigen sequence and involve covalent attachment of an immunostimulatory nucleotide sequence to an antigenic peptide sequence. Preferred antigenic peptides are fusion peptides made up of one or more CTL epitope peptides in sequence fused to a T helper peptide. | 2016-01-07 |